This trial is testing whether omitting MMF from the standard stem cell transplant treatment protocol is feasible, safe and potentially beneficial. 60 patients will be followed for up to 2 years to see what happens.
1 Primary · 7 Secondary · Reporting Duration: 1-year post-transplant and 2-years post-transplant
60 Total Participants · 1 Treatment Group
Primary Treatment: Omission of the drug mycophenolate mofetil · No Placebo Group · N/A
Age 18 - 75 · All Participants · 6 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: